ABIVAX Société Anonyme/€ABVX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About ABIVAX Société Anonyme
Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Primary listing
PAR
Employees
69
Headquarters
Website
ABVX Metrics
BasicAdvanced
€5.4B
-
-€3.09
0.13
-
Price and volume
Market cap
€5.4B
Beta
0.13
52-week high
€78.10
52-week low
€4.51
Average daily volume
14K
Financial strength
Current ratio
0.766
Quick ratio
0.674
Long term debt to equity
-103.281
Total debt to equity
-204.449
Interest coverage (TTM)
-13.11%
Profitability
EBITDA (TTM)
-185.652
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,244.03%
Operating margin (TTM)
-3,099.50%
Revenue per employee (TTM)
€90,000
Management effectiveness
Return on assets (TTM)
-57.74%
Return on equity (TTM)
-499.78%
Valuation
Price to revenue (TTM)
770.265
Price to book
-94.26
Price to tangible book (TTM)
-62.08
Price to free cash flow (TTM)
-34.117
Free cash flow yield (TTM)
-2.93%
Free cash flow per share (TTM)
-2.148
Growth
Revenue change (TTM)
-33.90%
Earnings per share change (TTM)
-1.57%
3-year revenue growth (CAGR)
39.30%
10-year revenue growth (CAGR)
28.28%
3-year earnings per share growth (CAGR)
3.18%
10-year earnings per share growth (CAGR)
9.86%
Bulls say / Bears say
Abivax completed enrollment for its Phase 3 ABTECT trials in ulcerative colitis on April 29, 2025, exceeding its target by 4% (1,275 vs. 1,224 patients) and maintaining a cash runway through the induction readout into Q4 2025 (Abivax IR).
Top-line Phase 3 induction results announced July 22, 2025 demonstrated that obefazimod 50 mg once daily achieved a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8 (p<0.0001), meeting all primary and key secondary endpoints with no new safety signals (Abivax IR).
On July 28, 2025 Abivax closed a $747.5 million underwritten public offering, netting approximately $700.3 million and extending its cash runway into Q4 2027 to support ongoing Phase 3 maintenance trials and prepare for NDA submissions (Abivax IR).
Abivax’s full-year 2024 financial results showed a cash balance of €144.2 million as of December 31, 2024, providing runway only into Q4 2025 without additional financing (Abivax IR).
The company’s net loss widened to €176.2 million in 2024, up from €147.7 million in 2023, reflecting elevated R&D and G&A spending ahead of any product revenue (Abivax IR).
Abivax reported zero revenue for 2024, underscoring its ongoing pre-commercial stage and reliance on external funding to support operations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ABIVAX Société Anonyme stock?
ABIVAX Société Anonyme (ABVX) has a market cap of €5.4B as of September 16, 2025.
What is the P/E ratio for ABIVAX Société Anonyme stock?
The price to earnings (P/E) ratio for ABIVAX Société Anonyme (ABVX) stock is 0 as of September 16, 2025.
Does ABIVAX Société Anonyme stock pay dividends?
No, ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next ABIVAX Société Anonyme dividend payment date?
ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for ABIVAX Société Anonyme?
ABIVAX Société Anonyme (ABVX) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.